We investigated menstrual irregularities after the first and second doses of the COVID-19 vaccine. Women answered a customised online questionnaire (ClinicalTrial.gov ID: NCT05083065) aimed to assess the vaccine type, the phase of the menstrual cycle during which the vaccine was administered, the occurrence of menstrual irregularities after the first and second doses, and how long this effect lasted. We excluded women with gynaecological and non-gynaecological diseases, undergoing hormonal and non-hormonal treatments, in perimenopause or menopause, as well as those who had irregular menstrual cycles in the last 12 months before vaccine administration. According to our data analysis, approximately 50-60% of reproductive-age women who received the first dose of the COVID-19 vaccine reported menstrual cycle irregularities, regardless of the type of administered vaccine. The occurrence of menstrual irregularities seems to be slightly higher (60-70%) after the second dose. Menstrual irregularities after both the first and second doses of the vaccine were found to self-resolve in approximately half the cases within two months. Based on these results, we suggest to consider these elements during the counselling of women who receive the COVID-19 vaccine, letting them know about the potential occurrence of temporary and self-limiting menstrual cycle irregularities in the subsequent month(s).

Evaluation of menstrual irregularities after COVID-19 vaccination: Results of the MECOVAC survey / Laganà, Antonio Simone; Veronesi, Giovanni; Ghezzi, Fabio; Ferrario, Marco Mario; Cromi, Antonella; Bizzarri, Mariano; Garzon, Simone; Cosentino, Marco. - In: OPEN MEDICINE. - ISSN 2391-5463. - 17:1(2022), pp. 475-484. [10.1515/med-2022-0452]

Evaluation of menstrual irregularities after COVID-19 vaccination: Results of the MECOVAC survey

Ferrario, Marco Mario;Bizzarri, Mariano
Conceptualization
;
2022

Abstract

We investigated menstrual irregularities after the first and second doses of the COVID-19 vaccine. Women answered a customised online questionnaire (ClinicalTrial.gov ID: NCT05083065) aimed to assess the vaccine type, the phase of the menstrual cycle during which the vaccine was administered, the occurrence of menstrual irregularities after the first and second doses, and how long this effect lasted. We excluded women with gynaecological and non-gynaecological diseases, undergoing hormonal and non-hormonal treatments, in perimenopause or menopause, as well as those who had irregular menstrual cycles in the last 12 months before vaccine administration. According to our data analysis, approximately 50-60% of reproductive-age women who received the first dose of the COVID-19 vaccine reported menstrual cycle irregularities, regardless of the type of administered vaccine. The occurrence of menstrual irregularities seems to be slightly higher (60-70%) after the second dose. Menstrual irregularities after both the first and second doses of the vaccine were found to self-resolve in approximately half the cases within two months. Based on these results, we suggest to consider these elements during the counselling of women who receive the COVID-19 vaccine, letting them know about the potential occurrence of temporary and self-limiting menstrual cycle irregularities in the subsequent month(s).
2022
COVID-19; abnormal uterine bleeding; adverse effect; menstrual irregularities; vaccine
01 Pubblicazione su rivista::01a Articolo in rivista
Evaluation of menstrual irregularities after COVID-19 vaccination: Results of the MECOVAC survey / Laganà, Antonio Simone; Veronesi, Giovanni; Ghezzi, Fabio; Ferrario, Marco Mario; Cromi, Antonella; Bizzarri, Mariano; Garzon, Simone; Cosentino, Marco. - In: OPEN MEDICINE. - ISSN 2391-5463. - 17:1(2022), pp. 475-484. [10.1515/med-2022-0452]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1682282
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 47
  • Scopus 76
  • ???jsp.display-item.citation.isi??? 59
social impact